Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark

American Journal of Cardiology

Volumn 105, Issue 11, 2010, Pages 1513-1519

  Jensen, Lisette Okkels ^a   Maeng, Michael ^b   Thayssen, Per ^a   Kaltoft, Anne ^b   Tilsted, Hans Henrik ^c   Lassen, Jens Flensted ^b   Hansen, Knud Noerregaard ^a   Bottcher, Morten ^b   Rasmussen, Klaus ^c   Madsen, Morten ^b   Johnsen, Søren Paaske ^b   Sørensen, Henrik Toft ^b   Thuesen, Leif ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CLOPIDOGREL; CYPHER; INSULIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BARE METAL STENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY THROMBOSIS; DENMARK; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77952430203     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.01.007     Document Type: Article

References (30)

1. Flaherty J.D., and Davidson C.J. Diabetes and coronary revascularization. JAMA 293 (2005) 1501-1508
2. Elezi S., Kastrati A., Pache J., Wehinger A., Hadamitzky M., Dirschinger J., Neumann F.J., and Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32 (1998) 1866-1873
3. Kornowski R., Mintz G.S., Kent K.M., Pichard A.D., Satler L.F., Bucher T.A., Hong M.K., Popma J.J., and Leon M.B. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation 95 (1997) 1366-1369
4. Jensen L.O., Thayssen P., Mintz G.S., Maeng M., Junker A., Galloe A., Christiansen E.H., Hoffmann S.K., Pedersen K.E., Hansen H.S., and Hansen K.N. Intravascular ultrasound assessment of remodelling and reference segment plaque burden in type-2 diabetic patients. Eur Heart J 28 (2007) 1759-1764
5. West N.E., Ruygrok P.N., Disco C.M., Webster M.W., Lindeboom W.K., O'Neill W.W., Mercado N.F., and Serruys P.W. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 109 (2004) 867-873
6. Jensen L.O., Maeng M., Kaltoft A., Thayssen P., Hansen H.H., Bottcher M., Lassen J.F., Krussel L.R., Rasmussen K., Hansen K.N., Pedersen L., Johnsen S.P., Soerensen H.T., and Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
7. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., Midwall J., Simonton C.A., Keim E., Wang P., Kuntz R.E., and Moses J.W. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
8. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., Gomez-Hospital J.A., Alfonso F., Hernandez-Antolin R., Goicolea J., Banuelos C., Escaned J., Moreno R., Fernandez C., Fernandez-Aviles F., and Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
9. Jensen L.O., Maeng M., Thayssen P., Christiansen E.H., Hansen K.N., Galloe A., Kelbaek H., Lassen J.F., and Thuesen L. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the randomized diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. Eur Heart J 29 (2008) 2733-2741
10. Maeng M., Jensen L.O., Galloe A.M., Thayssen P., Christiansen E.H., Hansen K.N., Helqvist S., Botker H.E., Lassen J.F., and Thuesen L. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 103 (2009) 345-349
11. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
12. Frank L. Epidemiology: when an entire country is a cohort. Science 287 (2000) 2398-2399
13. Andersen T.F., Madsen M., Jorgensen J., Mellemkjoer L., and Olsen J.H. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull 46 (1999) 263-268
14. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., and Serruys P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
15. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., and Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994) 583-612
16. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
17. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
18. Ortolani P., Balducelli M., Marzaroli P., Piovaccari G., Menozzi A., Guiducci V., Sangiorgio P., Tarantino F., Geraci G., Castriota F., Tondi S., Saia F., Cooke R.M., Guastaroba P., Grilli R., Marzocchi A., and Maresta A. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation 117 (2008) 923-930
19. Urban P., Gershlick A.H., Guagliumi G., Guyon P., Lotan C., Schofer J., Seth A., Sousa J.E., Wijns W., Berge C., Deme M., and Stoll H.P. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
20. Machecourt J., Danchin N., Lablanche J.M., Fauvel J.M., Bonnet J.L., Marliere S., Foote A., Quesada J.L., Eltchaninoff H., and Vanzetto G. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 50 (2007) 501-508
21. Ko D.T., Chiu M., Austin P.C., Bowen J., Cohen E.A., and Tu J.V. Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis. Am Heart J 156 (2008) 125-134
22. Billinger M., Beutler J., Taghetchian K.R., Remondino A., Wenaweser P., Cook S., Togni M., Seiler C., Stettler C., Eberli F.R., Luscher T.F., Wandel S., Juni P., Meier B., and Windecker S. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 29 (2008) 718-725
23. Hermiller J.B., Raizner A., Cannon L., Gurbel P.A., Kutcher M.A., Wong S.C., Russell M.E., Ellis S.G., Mehran R., and Stone G.W. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
24. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., Gomez-Hospital J.A., Alfonso F., Hernandez-Antolin R., Goicolea J., Banuelos C., Escaned J., Moreno R., Fernandez C., Fernandez-Aviles F., and Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
25. Maeng M., Jensen L.O., Kaltoft A., Hansen H.H., Bottcher M., Lassen J.F., Thayssen P., Krusell L.R., Rasmussen K., Pedersen L., Sorensen H.T., Johnsen S.P., and Thuesen L. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus. Am J Cardiol 102 (2008) 165-172
26. Scheen A.J., Warzee F., and Legrand V.M. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 25 (2004) 2167-2168
27. Daemen J., Garcia-Garcia H.M., Kukreja N., Imani F., de Jaegere P.P., Sianos G., van Domburg R.T., and Serruys P.W. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 (2007) 26-32
28. Ong A.T., Serruys P.W., Aoki J., Hoye A., van Mieghem C.A., Rodriguez-Granillo G.A., Valgimigli M., Sonnenschein K., Regar E., van der Ent M., de Jaegere P.P., McFadden E.P., Sianos G., van der Giessen W.J., de Feyter P.J., and van Domburg R.T. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45 (2005) 1135-1141
29. Lemos P.A., Serruys P.W., van Domburg R.T., Saia F., Arampatzis C.A., Hoye A., Degertekin M., Tanabe K., Daemen J., Liu T.K., McFadden E., Sianos G., Hofma S.H., Smits P.C., van der Giessen W.J., and de Feyter P.J. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
30. Garg P., Normand S.L., Silbaugh T.S., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., and Mauri L. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 118 (2008) 2277-2285